{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:25:26Z","timestamp":1789961126835,"version":"4.0.1"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["KJ2021A0239"],"award-info":[{"award-number":["KJ2021A0239"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.110036","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T01:52:33Z","timestamp":1679277153000},"page":"110036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Autoimmune pathogenesis, immunosuppressive therapy and pharmacological mechanism in aplastic anemia"],"prefix":"10.1016","volume":"117","author":[{"given":"Pengpeng","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-9319","authenticated-orcid":false,"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2023.110036_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3324\/haematol.2017.169862","article-title":"Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000\u20132011","volume":"102","author":"Vaht","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.intimp.2023.110036_b0010","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00277-021-04566-0","article-title":"Thai Aplastic Anemia Study, Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study","volume":"100","author":"Norasetthada","year":"2021","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.intimp.2023.110036_b0015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM199705083361906","article-title":"The pathophysiology of acquired aplastic anemia","volume":"336","author":"Young","year":"1997","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.intimp.2023.110036_b0020","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic Anemia","volume":"379","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imr.12935","article-title":"Transcriptional regulation of adaptive and innate lymphoid lineage specification","volume":"300","author":"Spinner","year":"2021","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1016\/j.intimp.2023.110036_b0030","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2011-08-368308","article-title":"Functional characterization of CD4+ T cells in aplastic anemia","volume":"119","author":"Kordasti","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00277-002-0602-0","article-title":"Increased inducible nitric oxide synthase expression and nitric oxide concentration in patients with aplastic anemia","volume":"82","author":"Chung","year":"2003","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110036_b0040","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2011-11-390708","article-title":"Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.intimp.2023.110036_b0045","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2010-01-266098","article-title":"Th17 immune responses contribute to the pathophysiology of aplastic anemia","volume":"116","author":"de Latour","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.intimp.2023.110036_b0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.4395.4395","article-title":"CD8+HLA-DR+ T Cells Are Increased in Patients with Severe Aplastic Anemia","volume":"120","author":"Shao","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2023.110036_b0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12185-017-2279-0","article-title":"TRAIL in CD8+ T cells from patients with severe aplastic anemia","volume":"106","author":"Liu","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.intimp.2023.110036_b0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaut.2013.06.004","article-title":"Promotion and prevention of autoimmune disease by CD8+ T cells","volume":"45","author":"Gravano","year":"2013","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/1074-7613(95)90051-9","article-title":"Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines","volume":"2","author":"Sad","year":"1995","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2023.110036_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1096-8652(200008)64:4<271::AID-AJH6>3.0.CO;2-C","article-title":"Type I and type II T-cell profiles in aplastic anemia and refractory anemia","volume":"64","author":"Tsuda","year":"2000","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.intimp.2023.110036_b0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41375-021-01231-3","article-title":"Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia","volume":"35","author":"Lundgren","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2023.110036_b0080","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-022-00909-x","article-title":"Natural killer cells in peripheral blood at diagnosis predict response to immunosuppressive therapy in severe aplastic anemia","author":"Yu","year":"2022","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.intimp.2023.110036_b0085","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/08820139.2014.888448","article-title":"Abnormalities of quantities and functions of natural killer cells in severe aplastic anemia","volume":"43","author":"Liu","year":"2014","journal-title":"Immunol Invest"},{"key":"10.1016\/j.intimp.2023.110036_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cellimm.2017.03.003","article-title":"Decreased TIM-3 expression of peripheral blood natural killer cells in patients with severe aplastic anemia","volume":"318","author":"Zhang","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.intimp.2023.110036_b0095","doi-asserted-by":"crossref","unstructured":"R.F. Duarte, M. Labopin, P. Bader, G.W. Basak, C. Bonini, C. Chabannon, S. Corbacioglu, P. Dreger, C. Dufour, A.R. Gennery, J. Kuball, A.C. Lankester, F. Lanza, S. Montoto, A. Nagler, R. Peffault de Latour, J.A. Snowden, J. Styczynski, I. Yakoub-Agha, N. Kroger, M. Mohty, B. European Society for, T. Marrow, Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019, Bone Marrow Transplant 54(10) (2019) 1525-1552.","DOI":"10.1038\/s41409-019-0516-2"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/bmt.2016.281","article-title":"Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia","volume":"52","author":"Xu","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.intimp.2023.110036_b0105","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2010.026682","article-title":"Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors","volume":"95","author":"Gupta","year":"2010","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.intimp.2023.110036_b0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.intimp.2023.110036_b0120","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.280758","article-title":"Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study","author":"Xu","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.25314","article-title":"Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party","volume":"94","author":"Samarasinghe","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1016\/j.intimp.2023.110036_b0130","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.bbmt.2018.05.015","article-title":"Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia","volume":"24","author":"Lu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.intimp.2023.110036_b0135","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.V91.7.2360","article-title":"Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins","volume":"91","author":"Genestier","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2023.110036_b0140","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1567-5769(02)00253-9","article-title":"Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells","volume":"3","author":"Monti","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0150","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.tp.0000244063.05338.27","article-title":"B-cell activity of polyclonal antithymocyte globulins","volume":"82","author":"Zand","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2023.110036_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107420","article-title":"Insights into the modulatory role of cyclosporine A and its research advances in acute inflammation","volume":"93","author":"Gui","year":"2021","journal-title":"International Immunopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2023.110036_b0160","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2023.110036_b0165","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0170","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2023.110036_b0175","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.17403","article-title":"Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries","volume":"194","author":"Scheinberg","year":"2021","journal-title":"Brit J Haematol"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0180","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-020-04271-4","article-title":"Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation","volume":"99","author":"Drexler","year":"2020","journal-title":"Annals of Hematology"},{"issue":"12","key":"10.1016\/j.intimp.2023.110036_b0185","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2023.110036_b0195","first-page":"11","article-title":"Evaluation of eltrombopag in patients with aplastic anemia in real-world experience","volume":"11","author":"Konishi","year":"2019","journal-title":"Leuk Res Rep"},{"issue":"12","key":"10.1016\/j.intimp.2023.110036_b0200","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag's promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation","volume":"101","author":"Di Buduo","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.molcel.2014.08.026","article-title":"5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation","volume":"56","author":"Hon","year":"2014","journal-title":"Mol Cell"},{"issue":"7472","key":"10.1016\/j.intimp.2023.110036_b0210","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature12750","article-title":"TET enzymes, TDG and the dynamics of DNA demethylation","volume":"502","author":"Kohli","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2023.110036_b0215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149856","article-title":"Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia","volume":"132","author":"Guan","year":"2022","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.intimp.2023.110036_b0220","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-gamma","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.intimp.2023.110036_b0225","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2018-01-826784","article-title":"Eltrombopag mobilizes iron in patients with aplastic anemia","volume":"131","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.110036_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114436","article-title":"Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron","volume":"186","author":"Ma","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"Roth","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010097","article-title":"Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia","volume":"22","author":"Di Paola","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"22","key":"10.1016\/j.intimp.2023.110036_b0245","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.intimp.2023.110036_b0250","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood-2012-05-432575","article-title":"Defective regulatory B-cell compartment in patients with immune thrombocytopenia","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.intimp.2023.110036_b0255","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia","volume":"386","author":"de Latour","year":"2022","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.intimp.2023.110036_b0265","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1210\/endo-109-6-1983","article-title":"The role of the androgen receptor in erythropoiesis","volume":"109","author":"Besa","year":"1981","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.intimp.2023.110036_b0270","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03345745","article-title":"Androgens and erythropoiesis: Past and present","volume":"32","author":"Shahani","year":"2009","journal-title":"J Endocrinol Invest"},{"issue":"9396","key":"10.1016\/j.intimp.2023.110036_b0275","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0140-6736(03)14797-6","article-title":"Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA","volume":"362","author":"Fogarty","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0280","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood-2003-01-0335","article-title":"Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome","volume":"102","author":"Yamaguchi","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0285","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2008-09-178871","article-title":"Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells","volume":"114","author":"Calado","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0290","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/16078454.2022.2081008","article-title":"The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.intimp.2023.110036_b0295","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00277-006-0152-y","article-title":"Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens","volume":"85","author":"Leleu","year":"2006","journal-title":"Annals of Hematology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0300","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbrc.2019.08.034","article-title":"Rapamycin ameliorates immune-mediated aplastic anemia by inhibiting the proliferation and metabolism of T cells","volume":"518","author":"Liu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.intimp.2023.110036_b0305","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.4049\/jimmunol.1000296","article-title":"A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation","volume":"185","author":"Haidinger","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2023.110036_b0310","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2001-11-0062","article-title":"Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway","volume":"99","author":"Ghosh","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2023.110036_b0315","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2023.110036_b0320","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110036_b0325","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V80.8.2012.2012","article-title":"Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products","volume":"80","author":"Colotta","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0330","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nyas.14059","article-title":"Cytokine-induced hematopoietic stem and progenitor cell mobilization: unraveling interactions between stem cells and their niche","volume":"1466","author":"de Kruijf","year":"2020","journal-title":"Ann Ny Acad Sci"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<185::AID-AJH2>3.0.CO;2-3","article-title":"Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin","volume":"59","author":"Shao","year":"1998","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.intimp.2023.110036_b0340","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2023.110036_b0345","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood-2006-07-034272","article-title":"Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)","volume":"109","author":"Socie","year":"2007","journal-title":"Blood"},{"issue":"9471","key":"10.1016\/j.intimp.2023.110036_b0350","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Brodsky","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0355","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.13396","article-title":"Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin","volume":"171","author":"Liu","year":"2015","journal-title":"Brit J Haematol"},{"issue":"9","key":"10.1016\/j.intimp.2023.110036_b0360","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(15)00147-7","article-title":"Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1\u20132 dose de-escalation study","volume":"2","author":"Anderlini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0365","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2141.2004.04917.x","article-title":"High-dose cyclophosphamide in severe aplastic anaemia","volume":"125","author":"Jones","year":"2004","journal-title":"Brit J Haematol"},{"issue":"9241","key":"10.1016\/j.intimp.2023.110036_b0370","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0140-6736(00)03126-3","article-title":"High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial","volume":"356","author":"Tisdale","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0375","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00277-022-04966-w","article-title":"A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia","volume":"101","author":"Jin","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2023.110036_b0385","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00277-020-04153-9","article-title":"Long-term follow-up of a novel immunosuppressive strategy of cyclosporine alternatively combined with levamisole for severe aplastic anemia","volume":"99","author":"Huo","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0390","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00277-022-04952-2","article-title":"First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience","volume":"101","author":"Hu","year":"2022","journal-title":"Annals of Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110036_b0395","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00277-020-04296-9","article-title":"Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine","volume":"100","author":"Lan","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110036_b0400","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00277-015-2308-0","article-title":"Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis","volume":"94","author":"Wei","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.intimp.2023.110036_b0405","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00277-009-0816-5","article-title":"Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia","volume":"89","author":"Gomez-Almaguer","year":"2010","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.intimp.2023.110036_b0410","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:53:42Z","timestamp":1761587622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":82,"alternative-id":["S1567576923003570"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110036","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune pathogenesis, immunosuppressive therapy and pharmacological mechanism in aplastic anemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110036"}}